Suppr超能文献

尿激酶型纤溶酶原激活剂在结直肠癌中的作用:与临床病理特征及患者预后的关系

Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

作者信息

Skelly M M, Troy A, Duffy M J, Mulcahy H E, Duggan C, Connell T G, O'Donoghue D P, Sheahan K

机构信息

Departments of Gastroenterology, Nuclear Medicine, and Pathology, St. Vincent's Hospital, Dublin 4, Ireland.

出版信息

Clin Cancer Res. 1997 Oct;3(10):1837-40.

PMID:9815571
Abstract

Urokinase-type plasminogen activator (u-PA) is a serine protease that has been implicated in cancer invasion and metastasis. We quantitated u-PA levels in normal colorectal mucosa, adenomatous polyps, and colorectal cancers and correlated these levels with clinicopathological features and patient survival. Detergent extracts were prepared from 133 colorectal cancers, 133 corresponding colorectal mucosal samples, and 15 synchronous adenomatous polyps. u-PA levels were determined using an ELISA, and a cancer:normal u-PA ratio was calculated for each case. u-PA levels were higher in cancers than in normal tissues, whereas adenomas had intermediate levels (P < 0.0001). u-PA levels were unrelated to clinical or pathological features. Survival was decreased in patients with a high cancer:normal u-PA ratio (P = 0.007). Multivariate survival analysis of patients undergoing curative surgery confirmed that the u-PA cancer:normal ratio was related to outcome (relative risk, 2.67; P = 0.02) and was independent of tumor stage (relative risk, 2.26; P = 0.03). Our study suggests that a high ratio of cancer to normal mucosal u-PA indicates an increased risk of colorectal cancer progression. Measurement of u-PA may provide useful prognostic information in patients undergoing curative surgery for colorectal cancer. The aggressive behavior of colorectal cancers with a high u-PA ratio suggests that the protease might be a suitable target for the development of therapeutic agents to prevent invasion and metastasis.

摘要

尿激酶型纤溶酶原激活剂(u-PA)是一种丝氨酸蛋白酶,与癌症侵袭和转移有关。我们对正常结直肠黏膜、腺瘤性息肉和结直肠癌中的u-PA水平进行了定量,并将这些水平与临床病理特征及患者生存率相关联。从133例结直肠癌、133例相应的结直肠黏膜样本和15例同步腺瘤性息肉中制备了去污剂提取物。使用酶联免疫吸附测定法(ELISA)测定u-PA水平,并计算每个病例的癌症与正常组织的u-PA比值。癌症中的u-PA水平高于正常组织,而腺瘤中的水平处于中间值(P < 0.0001)。u-PA水平与临床或病理特征无关。癌症与正常组织的u-PA比值高的患者生存率降低(P = 0.007)。对接受根治性手术的患者进行多变量生存分析证实,u-PA癌症与正常组织的比值与预后相关(相对风险,2.67;P = 0.02),且独立于肿瘤分期(相对风险,2.26;P = 0.03)。我们的研究表明,癌症与正常黏膜u-PA的高比值表明结直肠癌进展风险增加。测定u-PA可能为接受结直肠癌根治性手术的患者提供有用的预后信息。u-PA比值高的结直肠癌的侵袭性表明,该蛋白酶可能是开发预防侵袭和转移治疗药物的合适靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验